2D·

4.9 billion deal, Inari Medical

$SYK (+0,33%)


Stryker wants to buy Inari Medical for 4.9 billion dollars

The US medical technology provider Stryker wants to take over Inari Medical, another US-based company specializing in the treatment of vascular diseases. Is it currently worth buying Stryker shares?

The boards of Stryker and Inari have already agreed to the takeover, and Stryker will now make a cash offer of 80 dollars per Inari share. Inari's share price stood at 65 dollars at the close of trading on the US Nasdaq stock exchange yesterday evening. In total, Stryker expects the purchase to cost around 4.9 billion dollars.

Inari manufactures devices for the treatment of venous thromboembolism (VTE), a condition in which blood clots in the legs and in some cases can travel to the lungs. In the USA alone, up to 900,000 people are affected by VTE. The acquisition expands Stryker's offering in the treatment of peripheral vascular disease. The Group expects the acquisition to be completed in the first quarter of this year.

3
1 Comentar

imagem de perfil
I carefully added a little more
Participar na conversa